NOVO-NIZATIDINE 150 MG
NIZATIDINE : 150 MG · DIN 02240457 · NOVOPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is NOVO-NIZATIDINE?
NOVO-NIZATIDINE 150 MG contains NIZATIDINE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02240457, held by NOVOPHARM LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 03-May-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02240457 |
|---|---|
| Brand name | NOVO-NIZATIDINE |
| Generic / active ingredient | NIZATIDINE : 150 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | 150 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BA04 NIZATIDINE |
| AHFS class | 56:28.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 03-May-2018 |
| Original market date | 1999-07-23 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A02BA04 NIZATIDINE. 1 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AXID | 150 MG | CAPSULE | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00778338 |
| APO-NIZATIDINE | 150 MG | CAPSULE | APOTEX INC | CANCELLED POST MARKET | DIN 02220156 |
| APO-NIZATIDINE | 300 MG | CAPSULE | APOTEX INC | CANCELLED POST MARKET | DIN 02220164 |
| AXID | 300 MG | CAPSULE | PENDOPHARM DIVISION OF PHARMASCIENCE INC | DORMANT | DIN 00778346 |
| DOM-NIZATIDINE 150MG CAPSULES | 150 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02185814 |
| GEN-NIZATIDINE | 150 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | DIN 02246046 |
| GEN-NIZATIDINE | 300 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | DIN 02246047 |
| NIZATIDINE-150 | 150 MG | CAPSULE | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239558 |
| NIZATIDINE-300 | 300 MG | CAPSULE | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239559 |
| NOVO-NIZATIDINE | 300 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02240458 |
Who else supplies NIZATIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NIZATIDINE appears in 49 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.